Citations (12)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Julia Steinmetz-Späh & Per-Johan Jakobsson. (2023) The anti-inflammatory and vasoprotective properties of mPGES-1 inhibition offer promising therapeutic potential. Expert Opinion on Therapeutic Targets 27:11, pages 1115-1123.
Read now
Read now
Kok Yuen Ho, Mary S Cardosa, Sumapa Chaiamnuay, Rudy Hidayat, Huynh Quang Tri Ho, Ozlan Kamil, Sabarul A Mokhtar, Ken Nakata, Sandra V Navarra, Van Hung Nguyen, Rizaldy Pinzon, Shuichi Tsuruoka, Heng Boon Yim & Ernest Choy. (2020) Practice Advisory on the Appropriate Use of NSAIDs in Primary Care. Journal of Pain Research 13, pages 1925-1939.
Read now
Read now
Piet Geusens. (2009) Naproxcinod, a new cyclooxygenase-inhibiting nitric oxide donator (CINOD). Expert Opinion on Biological Therapy 9:5, pages 649-657.
Read now
Read now
Articles from other publishers (9)
Kizhakkeppurath Kumaran Ajeeshkumar, Kalladath Venugopal Vishnu, Raju Navaneethan, Kumar Raj, Kuttipurath Raghavan Remyakumari, Thangaraj Raja Swaminathan, Mathew Suseela, Kurukkan Kunnath Asha & Gopinathan Pillai Sreekanth. (2019) Proteoglycans isolated from the bramble shark cartilage show potential anti-osteoarthritic properties. Inflammopharmacology 27:1, pages 175-187.
Crossref
Crossref
Piet Geusens, Karel Pavelka, Jozef Rovensky, Johan Vanhoof, Nathalie Demeester, Mario Calomme & Dirk Vanden Berghe. (2017) A 12-week randomized, double-blind, placebo-controlled multicenter study of choline-stabilized orthosilicic acid in patients with symptomatic knee osteoarthritis. BMC Musculoskeletal Disorders 18:1.
Crossref
Crossref
Dixon Thomas, Zoya Ali, Seeba Zachariah, Kishore Gnana Sam Sundararaj, Matthew Van Cuyk & Jason C. Cooper. (2017) Coxibs Refocus Attention on the Cardiovascular Risks of Non-Aspirin NSAIDs. American Journal of Cardiovascular Drugs 17:5, pages 343-346.
Crossref
Crossref
Vaibhav A. DixitShirish Deshpande. (2016) Advances in Computational Prediction of Regioselective and Isoform-Specific Drug Metabolism Catalyzed by CYP450s.. ChemistrySelect 1:20, pages 6571-6597.
Crossref
Crossref
Jin Kyun Park, Kichul Shin, Eun-Ha Kang, You-Jung Ha, Yun Jong Lee, Kyung Hee Lee, Eun Young Lee, Yeong Wook Song, Yunhee Choi & Eun Bong Lee. (2016) Efficacy and Tolerability of GCSB-5 for Hand Osteoarthritis: A Randomized, Controlled Trial. Clinical Therapeutics 38:8, pages 1858-1868.e2.
Crossref
Crossref
Lisa Felden, Carmen Walter, Carlo Angioni, Yannick Schreiber, Nils von Hentig, Nerea Ferreiros, Gerd Geisslinger & Jörn Lötsch. (2014) Similar Maximum Systemic but not Local Cyclooxygenase-2 Inhibition by 50 mg Lumiracoxib and 90 mg Etoricoxib: A Randomized Controlled Trial in Healthy Subjects. Pharmaceutical Research.
Crossref
Crossref
K. C. Fok, C. J. Bell, R. B. Read, R. P. Eckstein & B. E. Jones. (2013) Lumiracoxib-induced cholestatic liver injury. Internal Medicine Journal 43:6, pages 731-732.
Crossref
Crossref
K. D. Rainsford. (2009) Ibuprofen: pharmacology, efficacy and safety. Inflammopharmacology 17:6, pages 275-342.
Crossref
Crossref
Katia Boniface, Kristian S. Bak-Jensen, Ying Li, Wendy M. Blumenschein, Mandy J. McGeachy, Terrill K. McClanahan, Brent S. McKenzie, Robert A. Kastelein, Daniel J. Cua & René de Waal Malefyt. (2009) Prostaglandin E2 regulates Th17 cell differentiation and function through cyclic AMP and EP2/EP4 receptor signaling. Journal of Experimental Medicine 206:3, pages 535-548.
Crossref
Crossref